Revenues Working Against CStone Pharmaceuticals' (HKG:2616) Share Price Following 35% Dive

CStone Pharmaceuticals (HKG:2616) shares have had a horrible month, losing 35% after a relatively good period beforehand. Of course, over the longer-term many would still wish they owned shares as the stock's price has soared 168% in the last twelve months.

After such a large drop in price, CStone Pharmaceuticals may be sending buy signals at present with its price-to-sales (or "P/S") ratio of 6.5x, considering almost half of all companies in the Biotechs industry in Hong Kong have P/S ratios greater than 9.7x and even P/S higher than 31x aren't out of the ordinary. However, the P/S might be low for a reason and it requires further investigation to determine if it's justified.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

See our latest analysis for CStone Pharmaceuticals

How Has CStone Pharmaceuticals Performed Recently?

While the industry has experienced revenue growth lately, CStone Pharmaceuticals' revenue has gone into reverse gear, which is not great. It seems that many are expecting the poor revenue performance to persist, which has repressed the P/S ratio. If this is the case, then existing shareholders will probably struggle to get excited about the future direction of the share price.

Want the full picture on analyst estimates for the company? Then our free report on CStone Pharmaceuticals will help you uncover what's on the horizon.

Is There Any Revenue Growth Forecasted For CStone Pharmaceuticals?

The only time you'd be truly comfortable seeing a P/S as low as CStone Pharmaceuticals' is when the company's growth is on track to lag the industry.

Taking a look back first, the company's revenue growth last year wasn't something to get excited about as it posted a disappointing decline of 12%. Still, the latest three year period has seen an excellent 67% overall rise in revenue, in spite of its unsatisfying short-term performance. Accordingly, while they would have preferred to keep the run going, shareholders would definitely welcome the medium-term rates of revenue growth.

Turning to the outlook, the next three years should generate growth of 7.8% each year as estimated by the dual analysts watching the company. With the industry predicted to deliver 55% growth per year, the company is positioned for a weaker revenue result.

With this in consideration, its clear as to why CStone Pharmaceuticals' P/S is falling short industry peers. Apparently many shareholders weren't comfortable holding on while the company is potentially eyeing a less prosperous future.

What We Can Learn From CStone Pharmaceuticals' P/S?

The southerly movements of CStone Pharmaceuticals' shares means its P/S is now sitting at a pretty low level. Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.

As we suspected, our examination of CStone Pharmaceuticals' analyst forecasts revealed that its inferior revenue outlook is contributing to its low P/S. Shareholders' pessimism on the revenue prospects for the company seems to be the main contributor to the depressed P/S. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.

We don't want to rain on the parade too much, but we did also find 1 warning sign for CStone Pharmaceuticals that you need to be mindful of.

If these risks are making you reconsider your opinion on CStone Pharmaceuticals, explore our interactive list of high quality stocks to get an idea of what else is out there.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.